Skye Bioscience Inc.
09/11/2026 | Press release | Distributed by Public on 09/11/2026 14:14
Management Change/Compensation, Termination of Material Agreement (Form 8-K)
Item 1.02 Termination of a Material Definitive Agreement.
On September 8, 2026, in connection with the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., a Nevada corporation (the "Company"), the Company provided written notice to Lohman & Associates, Inc. of its intent to terminate the Master Services Agreement, dated March 31, 2026, by and between the Company and Lohman & Associates, Inc. (the "Master Services Agreement"), effective September 8, 2026 (the "Effective Date").
The foregoing description of the Master Services Agreement is qualified in its entirety by reference to the full text of such agreement, which is filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2026 and is incorporated herein by reference.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Chief Financial Officer
On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company, effective as of the Effective Date.
Mr. Sharp's departure is not the result of any disagreement with the Company's independent auditors or the Company on any matter relating to the Company's financial statements, internal control over financial reporting, operations, policies or practices.
Appointment of Principal Financial and Accounting Officer
In connection with Mr. Sharp's departure, on September 9, 2026, the Board of Directors of the Company appointed Punit Dhillon, the Company's President and Chief Executive Officer, as the Company's principal financial and accounting officer, effective as of September 8, 2026. Mr. Dhillon will continue in his roles as Director, President and Chief Executive Officer of the Company.
The compensatory and other material terms of Mr. Dhillon's employment with the Company will remain unchanged in connection with the foregoing.
Biographical information for Mr. Dhillon can be found in the Company's definitive proxy statement for its 2026 annual meeting of stockholders filed with the Securities and Exchange Commission on April 16, 2026 and is incorporated herein by reference. There are no arrangements or understandings between Mr. Dhillon and any other persons pursuant to which he was appointed principal financial and accounting officer of the Company. There are also no family relationships between Mr. Dhillon and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Skye Bioscience Inc. published this content on September 11, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 11, 2026 at 20:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]